论文部分内容阅读
目的观察吉西他滨联合奥沙利铂和地塞米松治疗复发/难治性非霍奇金淋巴瘤的近期疗效和不良反应。方法对41例非霍奇金淋巴瘤患者在治疗第1、8天,给予吉西他滨1 000 mg/m~2;第2天,奥沙利铂100 mg/m~2;第1~4天,地塞米松40 mg/d,均采用静脉滴注,21~28 d为1个周期,至少完成2个周期后评价疗效。结果 41例患者中,25例获得缓解(60.98%),其中完全缓解9例(21.95%),部分缓解16例(39.02%)。主要不良反应表现为Ⅰ~Ⅲ度骨髓抑制和轻、中度的消化道反应。结论吉西他滨联合奥沙利铂和地塞米松治疗复发/难治性非霍奇金淋巴瘤近期疗效较好,不良反应小,安全性较高,值得进一步验证和推广。
Objective To observe the short-term efficacy and side effects of gemcitabine combined with oxaliplatin and dexamethasone in the treatment of relapsed / refractory non-Hodgkin’s lymphoma. Methods Forty-one patients with non-Hodgkin’s lymphoma were treated with gemcitabine 1 000 mg / m 2 on days 1 and 8. On the second day, oxaliplatin 100 mg / m 2; on day 1 to 4, Dexamethasone 40 mg / d, are used intravenous infusion, 21 ~ 28 d for a period of at least 2 cycles to complete the evaluation of the effect. Results Of the 41 patients, 25 were relieved (60.98%), of which 9 were completely relieved (21.95%) and 16 were partially relieved (39.02%). The main adverse reactions manifested as Ⅰ ~ Ⅲ degree myelosuppression and mild to moderate gastrointestinal reactions. Conclusion The combination of gemcitabine and oxaliplatin and dexamethasone in the treatment of relapsed / refractory non-Hodgkin’s lymphoma has better curative effect, less adverse reactions and higher safety, which deserves further verification and popularization.